JSPR

Jasper Therapeutics, Inc. NCM · JSPR

$0.88 +0.11 (+14.34%)

Blow-off · +2.33σ Hot zone Grade B

+ Compare Open in Sniper

Mkt cap $0.0B

P/E —

Day $0.58 – $1.03

52wk $0.31 – $1.65

Avg vol 1.3M

Beta 3.07

Div yld —

Next earnings 2026-08-13

Quick read

Plain English

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States.

JSPR last traded at $0.88, up 14.3% on the day; that's in the middle part of its 52-week range ($0.31–$1.65). Right now it's stretched well above its recent average — moves this fast often cool off or give some back.

The next scheduled earnings report (2026-08-13) is the biggest known catalyst on the calendar, and after a strong run, watch whether the price can hold its gains on quieter days.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

KC3 upper (deep stretch), +2.53 ATR from EMA21 — no notable pattern

Long —

score 19 · tech 19 / 80 · support 0 / 20

above KC1 lower, +2.53 ATR from EMA21 · no notable pattern

· Capitulation volume 9.7x — institutions transacting

How this grade was earned

total 19 pts

Cycle position 6

Volume 10

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short B

score 45 · tech 45 / 80 · support 0 / 20

KC3 upper (deep stretch), +2.53 ATR from EMA21 · no notable pattern

ℹ️ Deep stretch (KC3): stop is set wider to avoid a whipsaw, so the reward/risk reads lower (~1R) by design — not a worse trade.

· KC3 upper stretch — deepest mean-reversion tier
· Stochastic bear cross in overbought
· Volume 9.7x avg (no candle alignment)

How this grade was earned

total 45 pts

Cycle position 30

Momentum 6

Volume 3

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Candle-size grades

tap a size to open that chart

15m–30m–1h–4h–1DB

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Under the hood

On the latest daily bar, momentum is running hot (RSI 74, overbought territory), the trend is strong (ADX 28), and trading is unusually heavy at 9.6× normal volume.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI

0–100 · <30 oversold

Trend strength · ADX

>25 = strong trend

Volume vs avg

9.56×

1× = average

Stretch from avg

+2.5 ATR

− below · + above

Zone touches

tests of this zone

Suggested hold

5–60

bars (≈ days)

Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Debt / equity

0.22

lower = less leveraged

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Verdict

Unknown

Accounting quality Weak

✓ More cash than debt
✓ Current ratio 2.62 (antifragile)

⚠ Debt/equity 7.62 (fragile)
⚠ Negative retained earnings

Key statistics

All statistics →

JSPR is a $29 million company, it moves harder than the market (beta 3.1).

Mkt cap $0.0B

P/E ttm —

Fwd P/E -0.3

Beta 3.07

Day range $0.58 – $1.03

52w range $0.31 – $1.65

Avg vol 1.3M

RSI(2) 95.6

ROE -244.2%

Net mgn —

FCF mgn —

Debt/Eq 0.22

Div yld —

Sector Healthcare

Industry Biotechnology

Next earn 2026-08-13

52-week range · today's price

$0.31$1.65

More on JSPR

Options idea

See more →

CALL $2 2026-08-21

$0.15

ITM PUT $1 2026-09-18 · 63d

~$0.25

ITM PUT $1 2026-09-18 · 63d

~$0.25

ITM tracks the stock · OTM is cheaper / more leverage. Model-priced — verify the live chain. As of 13h ago (2026-07-17 20:47 UTC).

Earnings

See more →

Last reported: 2026-05-14
EPS (act / est): -0.38 / -0.54
Surprise: +30.1%
Next report: 2026-08-13

About

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the devel…